Compare Immunovant Inc. Common Stock (IMVT) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Sea Limited — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Sea Limited trades at $94.38 (market cap $57.98B). The key difference: Sea Limited is far larger — about 8.8× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Sea Limited for 102 Days on average.
| IMVT | SE | |
|---|---|---|
Market Cap | $6.62B | $57.98B |
Volume | 1,131,364 | 4,033,686 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $188.00 |
52-Week Low | $17.03 | $78.16 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $5.72B | $53.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sea Limited (SE) trades at $92.89, down 3.77% on the day, with bearish technical signals dominating despite strong fundamental growth. The company reported robust revenue growth from $22.94B in 2025 to $27.7B projected for 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing expectations but Q1 and Q2 2026 beating estimates. Analyst sentiment remains overwhelmingly positive with 70% buy ratings and a $153.67 consensus price target representing 65% upside potential.
The investment case hinges on Sea's continued e-commerce and fintech expansion, though the stock faces near-term technical pressure. Key risks include margin compression concerns and insider selling activity. With strong cash flow generation improving from negative $3.2B in 2022 to positive $2.34B in 2025, the fundamentals support long-term growth despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
